John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 9,800 shares at $179.78 ($1.7M) on 2021-06-01, disclosed to the SEC on 2021-06-03.
Open-market sale of $1.7M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $171.58 | 1,597 | $274K | 16.1% |
| 2 | $171.58 | 1,597 | $274K | 16.1% |
| 3 | $172.56 | 703 | $121K | 7.1% |
| 4 | $172.56 | 703 | $121K | 7.1% |
| 5 | $173.72 | 600 | $104K | 6.1% |
| 6 | $174.80 | 1,500 |
| $262K |
| 15.4% |
| 7 | $175.77 | 2,400 | $422K | 24.8% |
| 8 | $176.72 | 100 | $18K | 1.0% |
| 9 | $178.21 | 300 | $53K | 3.1% |
| 10 | $179.78 | 300 | $54K | 3.2% |
| Total | $173.88 avg | 9,800 | $1.7M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |